Moderna's skin cancer vaccine shows promise in trial
The vaccine is built on the mRNA platform that allowed Moderna to quickly roll out COVID-19 vaccines five years ago.
Moderna and Merck have announced the promising results of an experimental skin cancer vaccine, intismeran, in a recent trial. The vaccine, built on the same mRNA platform that enabled Moderna to rapidly develop COVID-19 vaccines, is genetically personalized to instruct the patient's immune system to target tumors and slow down the progression of melanoma.
This type of "neoantigen" vaccine has been considered a promising approach in cancer treatment, but this late-stage trial marked the first time it was used to definitively prove its effectiveness. The announcement has caused Moderna's shares to surge by more than 175%, with the company's CEO claiming that the results demonstrate the potential of an entirely new class of medicine.
Brief written by urgent.news from Semafor's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
